PRIOR AUTHORIZATION REQUEST FORM EOC ID:

Medicare Part D Tarceva (erlotinib)

Phone: 800-728-7947 Fax back to: 866-880-4532

Scott & White Prescription Services manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

	Prescriber Name: Supervising Physician:	
Patient Name:		
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):
Drug Name and Strength:		
Directions / SIG:		
Please attach any pertinent medical history or information for this patient that may support approval. Please answer the following questions and sign.		
Q1. Is the patient a NEW START to Tarceva (erlotinib) the	nerapy?	
☐ Yes		
□ No (describe Tarceva treatment history)		
Q2. What diagnosis is Tarceva being prescribed for?		
☐ Non-small cell lung cancer (NSCLC)		
Pancreatic Cancer - locally advanced, unresectable	or metastatic [Proceed to	Q6 & Q7]
☐ Other		
Q3. Please provide the ICD code from the diagnosis pro	vided.	
Q4. IF DIAGNOSIS IS NSCLC, how is Tarceva being us	ed in this patient (select o	one answer)?
☐ FIRST LINE treatment of METASTATIC NSCLC [Proceed to Q5 & Q7]		
☐ MAINTENANCE treatment of locally advanced or metastatic NSCLC in a patient whose disease has NOT		
PROGRESSED AFTER completing FOUR CYCLES of PLATINUM-based first-line chemotherapy [Proceed to Q7]		

PRIOR AUTHORIZATION REQUEST FORM EOC ID: Medicare Part D Tarceva

Medicare Part D Tarceva (erlotinib)

Phone: 800-728-7947 Fax back to: 866-880-4532

Scott & White Prescription Services manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

megible may delay the review process.	
Patient Name:	Prescriber Name: Supervising Physician:
☐ TREATMENT of locally advanced or metastatic CHEMOTHERAPY REGIMEN [Proceed to Q7] ☐ Other	NSCLC AFTER patient had failure with AT LEAST ONE PRIOR
EXON 21 (L858R) substitution mutations as detecte	STATIC NSCLC, does the patient have EGFR EXON 19 deletions or ed by an FDA-approved test?
<u> </u>	IOSE III I OONDINATION III OSMOITARINE
FIRST-LINE treatment for this patient?	ICER, will Tarceva be used in COMBINATION with GEMCITABINE as
☐ Yes ☐ No	
Q7. Is the prescriber an Oncologist or Hematologist	?
☐ Yes ☐ No	
Q8. Additional Comments:	
Prescriber Signature	Date

□ Expedited/Urgent - By checking this box and signing above, I certify that applying the standard review timeframe may seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

PRIOR AUTHORIZATION REQUEST FORM EOC ID: Medicare Part D Tarceva (erlotinib)

Phone: 800-728-7947 Fax back to: 866-880-4532

Scott & White Prescription Services manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

	Prescriber Name:
Patient Name:	Supervising Physician: